65,437 trials
Idiopathic Parkinson's Disease
Primary: Pulmonary Safety of CVT-301 Change From Baseline for FEV1. — 2.957; 3.117; -0.059; -0.078 Liters
Hepatitis B Vaccine
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 59; 62 Participants
Anaplastic Large-Cell Lymphoma · Non-Hodgkin Lymphoma · T-Cell Lymphoma
Primary: Progression-free Survival Per Independent Review Facility (IRF) — 48.20; 20.80 months
Post-laminectomy Pain Syndrome
Primary: Mean Change in Numeric Rating Scale (NRS) — -0.56; -0.54 units on a scale
Atopic Dermatitis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAEs) — 3; 6 Participants
Chronic Illness
Primary: Patient Perceived Continuity of Care From Multiple Providers- Management Continuity — -0.65; 4.0 units on a scale — p=0.02
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Primary: Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels — 26 Participants
Glucose Intolerance · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Chang in Disposition Index, a Measure of Beta Cell Function — 287; 314; -122; -129 units on a scale
Insomnia · Sleep
Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale
Chronic Venous Disorder · Venous Outflow Obstruction · Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Primary: Number of Participants With Major Adverse Events (MAE) — 0; 0; 0; 0 Participants
Healthy Subjects
Primary: Number (%) of Grade 2 or Higher AEs Regardless of Relationship to Study Drug — 1; 3 Participants
Decision Support Systems,Clinical · Skin Diseases
Primary: Number of Patients With Resolved Skin Problems — 72; 135 Participants — p=0.54
Sly Syndrome · MPS VII · Mucopolysaccharidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 12; 4; 9; 1 Participants
Prostate Cancer
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) or Serious Adverse Events (SAE) — 6; 8; 23; 5 participants
Diabetic Peripheral Neuropathy
Primary: Vibration Perception Threshold (VPT) — 9.26; -3.59; 9.18; 1.184 amplitude in microns